← Research library
Krystal Biotech
- Rating
- Price at publication
- $259.85
- Target price
- $325
- Stated upside
- +26%
- Horizon
- 12–18 months
- Published
- 10 April 2026
Thesis
Krystal Biotech delivers VYJUVEK, the world's first redosable gene therapy, with a pipeline across cystic fibrosis, oncology and ophthalmology.
Key risks
- 01All revenue comes from VYJUVEK until the pipeline matures (~2027–28)
- 02High short interest (9.88%)
- 03Slower pricing and reimbursement in the EU and Japan
Price, target and upside are as stated in the report on 10 April 2026, not updated since.
Full report
Open in a new tab ↗Educational research. This report reflects the views of its student author as of 10 April 2026. It is not investment advice or a recommendation to buy or sell any security. Full disclaimer.